Angelini Pharma, Inc.

With a career dedicated to delivering firsts in medicine and innovating to find new ways to treat patients, McKerracher’s expertise will help Genialis commercialize first-in-class biomarkers. BOSTON--(BUSINESS WIRE)-- Genialis, the RNA-biomarker company, today announced the appointment of Krista McKerracher as Chairperson of the Board of Directors. McKerracher is a seasoned biopharmaceutical leader passionate about bringing new medicines to patients with life-threatening diseases. Her background includes almost three decades at Johnson & Johnson and Novartis Oncology, where she held senior commercial and senior R&D leadership roles and launched several first-in-class drugs in the hematology/oncology space. McKerracher rounded out her drug development career at CRISPR Therapeutics, where she led the team that brought the first CRISPR Cas9 ex-vivo gene editing product to the clinic (HbF edited stem cells for hemoglobinopathies.) This press release features multimedia. View the full release here: Genialis Introduces Krista McKerracher as Chairperson of the Board. Pictured from left to right is the Genialis Board of Directors: Franck Brichory, Debiopharm Innovation Fund (observer); Cédric Odje, Debiopharm Innovation Fund; Krista McKerracher, Fig Advisory; Rafael Rosengarten, PhD, CEO & co-founder, Genialis; Miha Štajdohar, PhD, CTO & co-founder, Genialis; Elia Stupka, PhD, Angelini Ventures; Ita Lu, Taiwania Capital; Paoyen Lai, Taiwania Capital (observer) (Photo: Business Wire) McKerracher joins Cedric Odje, representing Debiopharm Innovation Fund; Ita Lu of Taiwania Capital; independent director Elia Stupka; and Genialis co-founders Rafael Rosengarten, Ph.D. (chief executive officer) and Miha Štajdohar, Ph.D. (chief technology officer) on the board. “Throughout my career, I’ve worked on a lot of firsts. Genialis has a promising opportunity to be the first to harness the vast amount of data contained in a small tumor sample and use that to bring reality to truly personalized medicine – delivering the right drug for the right patient at the right time,” said McKerracher. “When I was diagnosed with cancer in 2015, tumor sequencing was still brand new, and despite working in the field, many of my colleagues were skeptical about the value of sequencing for my tumor type because links to specific mutations were not well understood. With the Genialis approach to RNA-based biomarkers, I believe that in the future, all patients will have their tumors sequenced as standard of care. Genialis is on the leading edge of precision medicine, driving innovation and hope for patients globally.” Ms. McKerracher is an experienced public company board member known for bringing a solid commercial orientation to the drug development process. McKerracher graduated from the University of Waterloo (BSc. Hon. Applied Health Sciences) and earned an MBA from York University. “When we started our search for a board chair, we focused on finding someone who embraced our company value of ‘people first’ and committed to improving outcomes for patients globally,” said Dr. Rosengarten. “Krista brings the perspective of someone who has overseen the entire drug development life cycle on a global scale for some of the preeminent pharma companies, helping Genialis direct its biomarker algorithms to the most critical pain points in the process.” Genialis recently announced a breakthrough development in its predictive biomarker for KRAS inhibitor therapies and is currently enrolling select participants in its early access program. Genialis krasID is a new Artificial Intelligence classifier that accurately predicts response and clinical benefit to KRAS inhibitors across preclinical, clinical, and real-world settings. Most biomarkers in the KRAS space measure only KRAS mutation status, which may be necessary to receive the drug but is insufficient to predict or monitor response or to inform combinations or subsequent therapeutic interventions. By using high-dimensional gene expression data, Genialis krasID captures underlying biological complexity unique to each individual patient. Over 50 biopharma companies are currently developing more than 70 different KRAS-targeted drugs across over 12 disease indications. The total KRAS therapy market today is estimated at approximately $240 million, with a compound annual growth rate of 36% to reach $10 billion by 2032. Meanwhile, available diagnostics to support KRAS-targeted patient care are limited to mutation-based tests. Genialis is participating in the Festival of Genomics & BioData this week in Boston. Dr. Rosengarten will give a talk in the Live Lounge titled, “Genialis™ krasID: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapy” on Wednesday, June 12, 2024, from 12:10 PM to 12:40 PM EDT. To schedule a meeting at the Frontline Genomcis event, or learn more about Genialis biomarker programs, please visit or email biomarkers@genialis.com About Genialis Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data. For more information, please visit . View source version on businesswire.com: Contacts Source: Genialis Smart Multimedia Gallery Photo Genialis Introduces Krista McKerracher as Chairperson of the Board. Pictured from left to right is the Genialis Board of Directors: Franck Brichory, Debiopharm Innovation Fund (observer); Cédric Odje, Debiopharm Innovation Fund; Krista McKerracher, Fig Advisory; Rafael Rosengarten, PhD, CEO & co-founder, Genialis; Miha Štajdohar, PhD, CTO & co-founder, Genialis; Elia Stupka, PhD, Angelini Ventures; Ita Lu, Taiwania Capital; Paoyen Lai, Taiwania Capital (observer) (Photo: Business Wire) Logo View this news release and multimedia online at:

The medicines are indicated for usage as a second line treatment option for acute pain and primary dysmenorrhea. Credit: Kmpzzz / Shutterstock.com. Helsinn Group has renewed a distribution and licence agreement with Angelini Pharma for the commercialisation of AULIN and MESULID (Nimesulide) to treat acute short-term pain in six European countries. The territories covered under the renewed deal include Bulgaria, the Czech Republic, Hungary, Poland, Romania and the Slovak Republic. The non-selective, non-steroidal anti-inflammatory drugs AULIN and MESULID are offered on prescription as an oral tablet and granules for oral suspension. They are indicated for usage as a second-line treatment option for acute pain and primary dysmenorrhea. AULIN gel, also marketed under the brand name AulinDol, is available on prescription or over the counter. See Also: FDA accepts Sanofi’s Sarclisa sBLA for priority review South Korea’s MFDS approves Eisai-Biogen’s LEQEMBI for Alzheimer’s It is intended to provide symptomatic relief of pain linked to sprains and acute traumatic tendinitis. Helsinn Group CEO Dr Melanie Rolli stated: “We are pleased to have signed this agreement with Angelini and honoured to maintain our ongoing collaboration. “Our long-standing partnership with Angelini exemplifies how Helsinn fosters relationships and alliances to deliver essential products to patients. We appreciate their extensive reach in these countries, which enables patient access to this much-needed treatment.” Angelini Pharma International Operations executive vice-president Erik Lommerde stated: “We are delighted to renew our partnership with Helsinn. “This collaboration is built on a foundation of mutual trust, highlighted by our shared commitment to professional excellence, in-depth product knowledge, and high-quality service. This alliance is crucial for both parties and represents a strong business relationship.” In May 2023, Angelini Pharma and JCR Pharmaceuticals signed a global development and commercialisation agreement focused on developing novel biologic therapies. This collaboration utilises J-Brain Cargo technology to address epilepsy. JCR Pharmaceuticals received research expense reimbursements, upfront payments and milestone payments of $505.5m, in addition to tiered royalties on net product sales post-approval.

Angelini Ventures joins syndicate of top-tier international healthcare investors in Nouscom’s Series C financing round Financing will enable Nouscom to continue advancing the clinical development of its portfolio of neoantigen cancer vaccines to key clinical proof-of-concept endpoints Participation in this financing marks Angelini Ventures’ fourth life sciences investment in 2024 and its 15th since launching its €300 million BioTech and Digital Health fund in 2022 Rome, Italy, 21 March 2024 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions and ideas in BioTech and Digital Health, is pleased to announce its participation in an extension of the Series C financing round for Nouscom, a clinical stage immuno-oncology company based in Basel, Switzerland. Angelini Ventures’ investment of €7 million brings the total raised by Nouscom, in its oversubscribed Series C round – first announced in November 2023 – to €75.8 million (approx. $82 million). Angelini Ventures joins a syndicate of top-tier international healthcare investors through its participation in Nouscom’s financing, including new investors: Andera Partners, Bpifrance (through its InnoBio 2 fund), M Ventures, Revelation Partners, Indaco Venture Partners, Panakès Partners, XGen Ventures; existing investors: 5AM Ventures, EQT Life Sciences, Versant Ventures; and other undisclosed investors. The total proceeds of the Series C financing will enable Nouscom to continue advancing and expanding its wholly owned clinical pipeline to achieve multiple clinical value catalysts including: Readout from its ongoing randomized Phase 2 clinical trial for NOUS-209, an off-the-shelf cancer vaccine for the treatment of Mismatch Repair/Microsatellite Instable (dMMR/MSI) Metastatic Colorectal Cancer (mCRC) Phase 1b study completion and progression of NOUS-209 monotherapy in Lynch Syndrome (LS) carriers investigating the potential to intercept, prevent or delay cancer in high-risk individuals Phase 1b study completion for NOUS-PEV, a personalized cancer immunotherapy, in combination with a checkpoint inhibitor in patients with advanced melanoma and entry into randomized Phase 2 trials in indications with high unmet medical needs. Paolo Di Giorgio, Chief Executive Officer at Angelini Ventures, said: “In less than two years since launching our healthcare focused venture strategy, we have executed 15 global investments spanning biotechnology to digital health. Our aim is to promote innovation by investing in a portfolio of high-quality companies in Europe and North America that are transforming healthcare to improve patient outcomes. Our investment in Nouscom is a great example of the type of company we are interested in. We have been highly impressed with Nouscom’s team, best-in-class technology and advancing clinical pipeline, which is expected to deliver multiple catalysts in the coming years and, if positive, exciting new immunotherapy options for cancer patients.” Dr. Marina Udier, Chief Executive Officer at Nouscom, commented: “We are delighted to have extended our successful Series C financing round and excited to have Angelini Ventures on board. Their support strengthens our commitment to innovation and accelerates our journey towards delivering next-generation treatments for cancer patients.” Sergio Marullo di Condojanni, Chief Executive Officer of Angelini Industries, added: “As shareholders of Angelini Ventures, we look at opportunities that can be interesting not only in terms of return on investment but also to support ideas and new projects able to design high-impact solutions. This kind of investment fully responds to our long-term vision which is to take care of patients, communities, and nations, aiming to transform the future of the global health system.” *** Notes to Editors About Angelini Ventures Angelini Ventures, the venture capital arm of Angelini Industries, is an early-stage investment firm focused on accelerating disruptive innovations and trends in BioTech and Digital Health. The firm will invest €300 million across a global portfolio led by investment professionals and advisors in Europe, North America, and Asia. Angelini Ventures has deep domain expertise and leverages a global team, advisors, and strategic partners to help entrepreneurs scale their businesses into transformative category-leading companies. To date, Angelini Ventures has invested €80 million into 15 companies (five of which were created with Angelini Lumira Biosciences Fund) covering a range of therapeutic areas and modalities, including Cour Pharmaceuticals, Noctrix Health, Avation Medical, Pretzel Therapeutics, Cadence Neuroscience and Freya Biosciences. About Angelini Industries Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over 2 billion euros, generated in the health, industrial technology and consumer goods sectors. A targeted investment strategy for growth, constant commitment to research and development, deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates. About Nouscom Nouscom is a clinical-stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer immunotherapies. Nouscom’s proprietary viral vector platform has the capacity to encode for large payloads of neoantigens or other immunomodulators and clinically demonstrated to safely and potently harness the power of the immune system. Nouscom is currently advancing the clinical development of its wholly owned programs: NOUS-209, an off-the-shelf cancer immunotherapy for the treatment of MSI solid tumors in combination with pembrolizumab in randomized Phase 2 trials. In January 2023, Nouscom announced a clinical trial collaboration and pembrolizumab supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA). NOUS-209, an off-the-shelf monotherapy in Lynch Syndrome carriers with the potential to ‘intercept cancer’ before it occurs. A Phase 1b is being conducted under a clinical trial collaboration and supply agreement signed in 2022 with the National Cancer Institute (NCI) and a randomized Phase 2 trial is expected to be initiated in 2024. NOUS-PEV, a personalized cancer immunotherapy, is expected to enter randomized Phase 2 trials in indications with high unmet medical need in 2024. Nouscom has also exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms sponsored by Janssen Research & Development and Bristol Myers Squibb. For more information on Nouscom, please visit the company’s website at or follow us on LinkedIn. Contacts Angelini Ventures Paolo Di Giorgio, CEO Martina Palmese, Communications Coordinator martina.palmese@angeliniventures.com SEC Newgate Italia Daniele Pinosa daniele.pinosa@secnewgate.it Tel. +39 3357233872 Fausta Tagliarini fausta.tagliarini@secnewgate.it Tel. +39 3476474513 Daniele Murgia daniele.murgia@secnewgate.it Tel. +39 3384330031 MEDiSTRAVA (for press outside Italy) Sylvie Berrebi, Sandi Greenwood, Mark Swallow Sylvie.berrebi@medistrava.com Nouscom Rick Davis, COO info@nouscom.com